



Imaxio signs an option for a license agreement with a leading global animal health company to develop veterinary vaccines

Following an option agreement by Merial in December 2012, this new agreement confirms the interest in Imaxio's IMX313 technology, designed to improve the effectiveness of human and animal health vaccines

Lyon, France – June @@, 2013 – Imaxio, a biopharmaceutical company specialized in vaccines and genomics, announces today that it has signed a license option agreement with a major animal health laboratory, a top ten company globally in its sector. The aim of the agreement is to develop a number of veterinary vaccines using Imaxio's immunoenhancing IMX313 technology.

The agreement grants the partner permission to carry out its own evaluation of Imaxio's IMX313 technology and, subject to the results of the evaluation, provides the option of a license agreement to use IMX313 in developing vaccines for a total of four (4) animal health indications. The name of the partner as the technical and financial terms of the agreement, are not disclosed.

Imaxio's proprietary antigen re-engineering technology, IMX313, is designed to enhance the immune response and, therefore, the effectiveness of vaccines with which it is combined. IMX313 offers significant potential as a solution to developing vaccines for major indications, in response to the challenge posed by some human and animal health candidates which lack effectiveness.

'This new agreement with a major player in veterinary pharmacy is a further boost to our confidence in the IMX313 technology, following Imaxio signing the license option with Merial last December. The IMX313 technology is crucial to our continued in-house development of vaccines for tuberculosis, flu, staphylococcus aureus and veterinary cryptosporidiosis,' explains Alexandre Le Vert, Chief Executive Officer of Imaxio. 'We are delighted to have secured promising collaboration agreements with renowned academic and industrial partners. This enables us to promote the use of IMX313 in the development of vaccines and immunotherapies for use in additional indications. We are keen to build on our initial success, and are therefore continuing to seek out potential partners.'

About Imaxio SA

Imaxio SA is a biopharmaceutical company specialized in the areas of vaccines and genomics.

Using IMX313, its antigen re-engineering technology, Imaxio is developing, both individually and with its partners, recombinant vaccines with improved effectiveness for applications in both human and animal health. In France, Imaxio already markets Spirolept®, a human vaccine indicated for preventing a professional infectious disease, and Trolovol®, an orphan drug indicated for a congenital metabolic disease.

Imaxio's genomics division undertakes diagnostic and therapeutic research in the field of oncology and immunology, as well as providing services in the areas of human health, the agro-food business and the environment.

Imaxio was created through the merger between Diagnogene and Avidis, a spin-off from the Medical Research Council and Cambridge University in the UK. The company owns well-founded intellectual property and collaborates with numerous academic partners, including the Jenner Institute at Oxford University.

Imaxio SA is based in Lyon and at Saint Beuzire, near Clermont-Ferrand in France. It has 24 employees, twelve of whom are engaged in R&D. In 2012 it delivered a turnover of EUR 2.7 million.

For more information, go to: <http://www.imaxio.com> and <http://www.genomics-imaxio.com>

For further information, please contact:

Andrew Lloyd and Associates
Celine Gonzalez / Neil Hunter
celine@ala.com / neil@ala.com
Tel : +44 1273 675100
